Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) is a globally diversified conglomerate based in Washington, D.C., focusing primarily on life sciences and diagnostics. Founded in 1984 by Stephen and Mitchell Rales, the company has transitioned from a real estate organization into a leading player in the medical, industrial, and commercial products sectors.
Danaher designs, manufactures, and markets a variety of innovative products, particularly scientific instruments and consumables. The company has recently revamped its portfolio by divesting its environmental and applied solutions group, Veralto, in late 2023. This strategic move has allowed Danaher to concentrate its efforts on advancing health through science and technology.
Among Danaher's notable achievements is the acquisition of Abcam plc, which enhances its capabilities in proteomics—an expanding field within life sciences. The company is also known for its contribution to gene-editing therapies through a collaboration with the Innovative Genomics Institute (IGI), aiming to develop CRISPR-based treatments for various diseases.
Danaher's portfolio includes well-known subsidiaries like Beckman Coulter Life Sciences, Integrated DNA Technologies, and Aldevron. These subsidiaries focus on delivering innovative solutions in diagnostics, genomics, and biomanufacturing. For instance, Beckman Coulter's recent partnership with Curiox Biosystems aims to provide automated sample preparation for flow cytometry, enhancing research efficiency.
Financially, Danaher reported better-than-expected revenue in the fourth quarter of 2023, bolstered by strong performance in its life sciences and diagnostics segments. The company's strategic divestitures and acquisitions have positioned it for long-term growth and increased shareholder value.
Danaher’s ongoing projects include a collaboration with Cincinnati Children's Hospital to improve liver organoid technology for drug toxicity screening. This initiative is part of the Danaher Beacons program, which funds pioneering academic research to develop next-generation medical technologies. Another significant collaboration is with Johns Hopkins University, focusing on diagnosing mild traumatic brain injuries (TBI) using advanced biomarker panels.
Overall, Danaher's commitment to scientific excellence, innovation, and continuous improvement makes it a crucial player in advancing healthcare globally. With over 63,000 associates worldwide, Danaher is dedicated to improving quality of life and laying the groundwork for a healthier, more sustainable future.
SCIEX, a member of Danaher Corporation (NYSE:DHR), has launched SCIEX OS software v3.0 at ASMS 2022, aiming to enhance laboratory efficiency and integration. The software supports their mass spectrometry portfolio and introduces features such as Zeno SWATH DIA and stMRM, promoting superior data quality and workflow enhancements. The new Central Administration Console simplifies project management and security, while accessibility has been boosted with support for nine languages, enabling a global reach.
Danaher Corporation (NYSE: DHR) has joined the Bespoke Gene Therapy Consortium (BGTC) to enhance the development of customized gene therapies for rare diseases. Launched in October 2021, the BGTC aims to create efficient, cost-effective resources for the research community. Collaborating with key health organizations, Danaher will contribute its significant expertise in genomic medicines through its subsidiaries, including Pall Corporation and Cytiva. This initiative seeks to address challenges in the current drug development model, facilitating faster and more affordable solutions for patients in need.
Danaher Corporation (NYSE: DHR) announced a quarterly cash dividend of $0.25 per share for its common stock, payable on July 29, 2022, to shareholders of record by June 24, 2022. Additionally, a dividend of $12.50 per share for its 5.00% Series B Mandatory Convertible Preferred Stock will be paid on July 15, 2022, to record holders by June 30, 2022. This reflects Danaher's commitment to returning value to its shareholders while maintaining its operational strengths across various markets.
At TIDES 2022, SCIEX announced the launch of the RNA 9000 Purity & Integrity kit designed for high-resolution analysis of mRNA therapeutics. This kit enhances the integrity and quality control of RNA, essential for RNA-based therapeutics and vaccines amidst a growing demand. The kit is compatible with the BioPhase 8800 and PA 800 Plus systems, streamlining analysis and reducing time to market. It allows scientists to accurately gauge therapeutic sizes and detect low-level impurities, ultimately supporting the development of impactful RNA medicines.
Danaher Corporation (NYSE: DHR) announced that CEO Rainer M. Blair will present at the Bank of America Securities Health Care Conference in Las Vegas, Nevada, on May 11, 2022, at 10:00 a.m. PT. The event will be webcast live on Danaher’s official website. Danaher is a global innovator in science and technology, focusing on solving complex challenges in health care, environmental, and applied markets. With approximately 80,000 associates, Danaher operates through over 20 companies united by its business system and shared purpose of 'Helping Realize Life's Potential.'
Danaher Corporation (NYSE: DHR) announced its Q1 2022 results, reporting net earnings of $1.7 billion ($2.31 per diluted share), marking a 1.0% year-over-year increase. Non-GAAP adjusted diluted net earnings rose 9.5% to $2.76 per share. Revenues hit $7.7 billion, reflecting a 12.0% increase, with 12.0% non-GAAP core revenue growth. Operating cash flow stood at $2.0 billion. For Q2 2022, non-GAAP base business core revenue growth is projected in the mid-single digits, impacted by COVID-19 shutdowns in China. The full year 2022 growth is expected in the high-single digits.
Danaher Corporation (NYSE: DHR) announced that its 4.75% Series A Mandatory Convertible Preferred Stock will convert into common stock on April 15, 2022. Each share of Preferred Stock will convert at a rate of 6.6632 shares of Common Stock. Holders of record as of March 31, 2022, will also receive a final quarterly cash dividend of $11.875 per share on the Preferred Stock. This move reflects Danaher's commitment to enhancing shareholder value and streamlining capital structure.
Integrated DNA Technologies (IDT) has partnered with Catalytic Data Science as part of its Align Program to enhance next-generation sequencing (NGS) solutions. Catalytic Data Science will promote IDT's rhAmpSeq CRISPR Analysis System, which integrates advanced data analysis technology with IDT's CRISPR genome editing reagents. This collaboration aims to improve the efficiency of genomic research and was highlighted by a 2021 award for innovation. IDT, known for its nucleic acid products, supports over 130,000 life science researchers globally.
Danaher Corporation (NYSE: DHR) will host a quarterly earnings conference call for Q1 2022 on April 21, 2022, at 8:00 a.m. ET. The call can be accessed via webcast on Danaher's website in the Investors section, alongside a presentation. A replay will be available after the call until May 5, 2022, and can be accessed via phone or the website. Danaher, a leader in healthcare and technology, aims to aid customers in overcoming challenges globally, boasting a team of approximately 80,000 associates.
Integrated DNA Technologies (IDT) has announced that the Munich Leukemia Laboratory (MLL) has joined its Align Program, following the launch of IDT's xGen™ NGS portfolio in December. This partnership aims to promote genomics research by leveraging MLL's expertise in sequencing exomes, genomes, and transcriptomes, along with IDT's advanced NGS solutions. MLLSEQ, MLL's sequencing label, will now be available to researchers beyond healthcare. The Align Program enhances access to innovative NGS tools, contributing to advancements in cancer research and diagnostics.
FAQ
What is the current stock price of Danaher Corporation (DHR)?
What is the market cap of Danaher Corporation (DHR)?
What does Danaher Corporation specialize in?
Who founded Danaher Corporation and when?
Where is Danaher Corporation headquartered?
What recent divestiture has Danaher Corporation made?
What are some of Danaher's notable subsidiaries?
What recent acquisition has enhanced Danaher's capabilities in proteomics?
What is the Danaher Beacons program?
What collaboration is Danaher involved in to improve liver organoid technology?
What is the focus of Danaher's partnership with Johns Hopkins University?
How does Danaher contribute to the field of gene-editing therapies?
